GH.NADERIAN, MD

21
GH.NADERIAN, MD

description

GH.NADERIAN, MD. GH.NADERIAN MD. Chloroquine maculopathy Chloroquine ( CQ) Hydroxychloroquine (HCQ). The first reports concerned long term use of CQ for malaria and later reports showed retinopathy after treatment of anti- inflammatory disease. GH.NADERIAN, MD. - PowerPoint PPT Presentation

Transcript of GH.NADERIAN, MD

GH.NADERIAN, MD

2

GH.NADERIAN MD

3

Chloroquine maculopathy

Chloroquine ( CQ)Hydroxychloroquine (HCQ)

4

The first reports concerned long term use of CQ for malaria and later reports showed retinopathy after treatment of anti- inflammatory disease

GH.NADERIAN, MD

5

The mechanism of CQ and HCQ toxicity is not well understood

a)Acute effects on the metabolism of retinal cells

b)Bind to melanin in the RPE

6

The clinical picture of CQ and HCQ toxicity is characterized classically by bilateral bulls eye

GH.NADERIAN, MD

7

Factors increasing the risk of CQ and HCQ retinopathy:

GH.NADERIAN, MD

Duration8

Duration of use >5 years

GH.NADERIAN, MD

Cumulative dose 9

HCQ > 1000 gr (total) CQ > 460 gr (total)

GH.NADERIAN, MD

Daily dose10

HCQ > 400 mg / dayCQ > 250 mg / day

GH.NADERIAN, MD

Age11

Age : Elderly

GH.NADERIAN, MD

12

Systemic disease : kidney or liver dysfunction

GH.NADERIAN, MD

13

Ocular disease : retinal disease or maculopaty

GH.NADERIAN, MD

14

Genetic factors ??

GH.NADERIAN, MD

American Academy Of Ophthalmology (feb 2011) 15

Recommendations on screening for CQ and HCQ retinopathy

GH.NADERIAN, MD

Time line 16

a)Base line examination within first year of use

b)Annual screening after 5 years of use

GH.NADERIAN, MD

Recommended screenig procedures

17

Ocular examination Automated visual field

GH.NADERIAN, MD

18

In addition , if available , perform one or more of the following objective tests

SD - OCT mf ERGFAF (fundus auto fluroscence)

Not recommended for screening 19

Fundus photography Time –domain OCT FAAmsler grid Color testing EOG

20

Thanks for your attention